Open Access Open Access  Restricted Access Subscription or Fee Access

Expression of CD31, vWF, and VE-Cadherin in HUVECs via Immunofluorescence

Rajan Narayan, Anupama Kakkar, Rinkey Sharma, Rohit Chamoli, Gaurav Nigam, Nitul Sharma


Endothelial cells, the lining cells of blood vessels, are involved in many physiological and pathophysiological process, including hemostasis, vasoregulation, inflammation, angiogenesis, and the extravasation of fluids, macromolecules, hormones and leucocytes. This work was carried out to investigate the expression of certain cell surface markers of human umbilical vein endothelial cells (HUVECs) in vitro via immunocytochemistry. Immunocytochemistry helped in anatomic visualization of the localization of a specific protein or antigen in endothelial cells, which were positively stained for endothelial cells marker. The cells produced from this technique grew well for extended periods and retained the normal characteristics of primary HUVECs, making them invaluable tool for researchers.


CD 31, HUVECs, immunocytochemistry, VE-cadherin, vWF

Full Text:



Cines D.B., Pollak E.S., Buck C.A., et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders, Blood. 2015; 91: 3527–61p.

Aird W.C. Endothelial cell heterogeneity, Crit Care Med. 2003; 31: 221–30p.

Lin S., Tang S., HuJ., et al. Culture and identification of human vascular endothelial cells, Yan. Kexuc Bao. 2012; 16(2): 131–4p.

Nachman R.L., Jaffe E.A. Endothelial cell culture: beginning of modern vascular bilogy, J Clin Invest. 2004; 114(8): 1037–40p.

Larrivee B., Karsan A. Isolation and culture of primary endothelial cells, Methods Mol Biol. 2005; 290: 315–29p.

Rafii S., Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration, Nat Med. 2003; 9: 702–12p.

Majka S.M., Jackson K.A., Kienstra K.A., et al. Distinct progenitor populations in skeletal muscle are bone marrow derived and exhibit different cell fates during vascular regeneration, J Clin Invest. 2003; 111: 71–9p.

Sueishi K., Yonemitsu Y., Nakagawa K., et al. Atherosclerosis and angiogenesis. Its pathophysiological significance in humans as well as in an animal model induced by the gene transfer of vascular endothelial growth factor, Ann NY Acad Sci. 1997; 811: 311–24p.

Celletti F.L., Waugh J.M., Amabile P.G., et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression, Nat Med. 2001; 7: 425–9p.

Moulton K.S., Vakili K., Zurakowski D., et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis, Proc Natl Acad Sci USA. 2003; 100: 4736–41p.

Lemstrom K.B., Krebs R., Nykanen A.I., et al. Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis, Circulation. 2002; 105: 2524–30p.

Cho C.H., Kammerer R.A., Lee H.J., et al. Designed angiopoietin-1 variant, COMP-Ang1, protects against radiation-induced endothelial cell apoptosis, Proc Natl Acad Sci USA. 2004; 101: 5553–8p.

He Y., Karpanen T., Alitalo K. Role of lymphangiogenic factors in tumor metastasis, Biochim Biophys Acta. 2004; 16543–12p.

Dadras S.S., Paul T., Bertoncini J., et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival, Am J Pathol. 2003; 162: 1951–60p.

Padera T.P., Kadambi A., di Tomaso E., et al. Lymphatic metastasis in the absence of functional intratumor lymphatics, Science. 2002; 296: 1883–6p.

Scholz D., Cai W.J., Schaper W. Arteriogenesis a new concept of vascular adaptation in occlusive disease, Angiogenesis. 2001; 4: 247–57p.

Autiero M., Waltenberger J., Communi D., et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1, Nat. Med. 2003; 9: 936–43p.

Luttun A., Tjwa M., Moons L., et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1, Nat Med. 2002; 8: 831–40p.

Bellomo D., Headrick J.P., Silins G.U., et al. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia, Circ Res. 2000; 86: E29–35p.



  • There are currently no refbacks.